S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
US Dollar Replaced By "Biden Bucks"? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
US Dollar Replaced By "Biden Bucks"? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
US Dollar Replaced By "Biden Bucks"? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
US Dollar Replaced By "Biden Bucks"? (Ad)
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Apple (AAPL) is making moves behind the scenes to prepare for a downturn... (Ad)
NYSE:PKI

PerkinElmer - PKI Stock Forecast, Price & News

$157.91
-3.05 (-1.89%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$156.72
$162.31
50-Day Range
$132.37
$160.96
52-Week Range
$130.65
$203.16
Volume
1.55 million shs
Average Volume
791,945 shs
Market Capitalization
$19.93 billion
P/E Ratio
29.57
Dividend Yield
0.18%
Price Target
$161.13

PerkinElmer MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
2.0% Upside
$161.13 Price Target
Short Interest
Bearish
5.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
0.11mentions of PerkinElmer in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$2.08 M Sold Last Quarter
Proj. Earnings Growth
-15.58%
From $7.83 to $6.61 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

Computer And Technology Sector

318th out of 665 stocks

Analytical Instruments Industry

11th out of 31 stocks

PKI stock logo

About PerkinElmer (NYSE:PKI) Stock

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Analyst Ratings Changes

Several brokerages recently issued reports on PKI. Robert W. Baird increased their price objective on PerkinElmer from $198.00 to $202.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 2nd. Barclays increased their price objective on PerkinElmer from $125.00 to $149.00 and gave the stock an "underweight" rating in a research note on Tuesday, August 2nd. The Goldman Sachs Group reduced their price objective on PerkinElmer from $200.00 to $175.00 and set a "neutral" rating for the company in a research note on Thursday, July 14th. Citigroup dropped their target price on PerkinElmer from $185.00 to $170.00 in a research report on Wednesday, May 4th. Finally, Bank of America lowered PerkinElmer from a "buy" rating to a "neutral" rating and set a $178.00 target price on the stock. in a research report on Tuesday, August 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $161.13.

PerkinElmer Stock Performance

Shares of NYSE:PKI opened at $157.91 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 2.02. The firm has a market cap of $19.93 billion, a price-to-earnings ratio of 29.57, a P/E/G ratio of 0.44 and a beta of 1.12. The business's 50-day simple moving average is $145.45 and its 200-day simple moving average is $158.49. PerkinElmer has a 52 week low of $130.65 and a 52 week high of $203.16.

PerkinElmer (NYSE:PKI - Get Rating) last issued its quarterly earnings data on Monday, August 1st. The medical research company reported $2.32 EPS for the quarter, beating analysts' consensus estimates of $2.01 by $0.31. The business had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.20 billion. PerkinElmer had a return on equity of 16.68% and a net margin of 13.21%. The firm's revenue for the quarter was up .1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.83 EPS. As a group, equities research analysts expect that PerkinElmer will post 7.83 earnings per share for the current fiscal year.

PerkinElmer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 11th. Stockholders of record on Friday, October 21st will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.18%. The ex-dividend date of this dividend is Thursday, October 20th. PerkinElmer's dividend payout ratio is 5.24%.

Insider Buying and Selling at PerkinElmer

In other PerkinElmer news, insider Andrew Okun sold 3,173 shares of the firm's stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $165.42, for a total value of $524,877.66. Following the sale, the insider now owns 6,391 shares of the company's stock, valued at approximately $1,057,199.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other PerkinElmer news, insider Andrew Okun sold 3,173 shares of the firm's stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $165.42, for a total value of $524,877.66. Following the completion of the sale, the insider now owns 6,391 shares in the company, valued at approximately $1,057,199.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Daniel R. Tereau sold 5,700 shares of the firm's stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $145.14, for a total value of $827,298.00. Following the completion of the sale, the insider now owns 13,380 shares of the company's stock, valued at approximately $1,941,973.20. The disclosure for this sale can be found here. Insiders have sold 13,898 shares of company stock valued at $2,083,263 in the last 90 days. 0.52% of the stock is currently owned by insiders.

Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PKI Stock News Headlines

PerkinElmer (NYSE:PKI) PT Raised to $202.00
Company News for Aug 2, 2022
PerkinElmer: Q2 Earnings Insights - Benzinga
See More Headlines
Receive PKI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PerkinElmer and its competitors with MarketBeat's FREE daily newsletter.

PKI Company Calendar

Ex-Dividend for 8/12 Dividend
7/21/2022
Last Earnings
8/01/2022
Dividend Payable
8/12/2022
Today
8/14/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
Life Sciences Tools & Services
CUSIP
71404610
Employees
16,700
Year Founded
1937

Price Target and Rating

Average Stock Price Forecast
$161.13
High Stock Price Forecast
$205.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+2.0%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$943.16 million
Pretax Margin
18.24%

Debt

Sales & Book Value

Annual Sales
$5.07 billion
Cash Flow
$13.67 per share
Book Value
$56.78 per share

Miscellaneous

Free Float
125,568,000
Market Cap
$19.93 billion
Optionable
Optionable
Beta
1.12

Social Links















PKI Stock - Frequently Asked Questions

Should I buy or sell PerkinElmer stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PKI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PKI, but not buy additional shares or sell existing shares.
View PKI analyst ratings
or view top-rated stocks.

What is PerkinElmer's stock price forecast for 2022?

7 brokerages have issued 1 year target prices for PerkinElmer's stock. Their PKI share price forecasts range from $50.00 to $205.00. On average, they expect the company's share price to reach $161.13 in the next twelve months. This suggests a possible upside of 2.0% from the stock's current price.
View analysts price targets for PKI
or view top-rated stocks among Wall Street analysts.

How have PKI shares performed in 2022?

PerkinElmer's stock was trading at $201.06 at the beginning of the year. Since then, PKI shares have decreased by 21.5% and is now trading at $157.91.
View the best growth stocks for 2022 here
.

When is PerkinElmer's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our PKI earnings forecast
.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) posted its quarterly earnings results on Monday, August, 1st. The medical research company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.31. The medical research company earned $1.23 billion during the quarter, compared to analysts' expectations of $1.20 billion. PerkinElmer had a trailing twelve-month return on equity of 16.68% and a net margin of 13.21%. PerkinElmer's revenue was up .1% compared to the same quarter last year. During the same period last year, the firm posted $2.83 EPS.

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Friday, July 22nd. Stockholders of record on Friday, October 21st will be paid a dividend of $0.07 per share on Friday, November 11th. This represents a $0.28 annualized dividend and a yield of 0.18%. The ex-dividend date of this dividend is Thursday, October 20th.
Read our dividend analysis for PKI
.

Is PerkinElmer a good dividend stock?

PerkinElmer (NYSE:PKI) pays an annual dividend of $0.28 per share and currently has a dividend yield of 0.17%. The dividend payout ratio is 5.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, PKI will have a dividend payout ratio of 4.24% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for PKI.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer updated its third quarter 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of $1.40-$1.45 for the period, compared to the consensus earnings per share estimate of $1.34. The company issued revenue guidance of $1.02 billion-$1.03 billion, compared to the consensus revenue estimate of $1.01 billion.

What is Prahlad Singh's approval rating as PerkinElmer's CEO?

27 employees have rated PerkinElmer Chief Executive Officer Prahlad Singh on Glassdoor.com. Prahlad Singh has an approval rating of 79% among the company's employees.

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD), Bristol-Myers Squibb (BMY), CVS Health (CVS), Abbott Laboratories (ABT) and Intel (INTC).

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by many different retail and institutional investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (3.66%), Pictet Asset Management SA (2.32%), Primecap Management Co. CA (1.07%), Northern Trust Corp (1.01%), Robeco Schweiz AG (0.99%) and King Luther Capital Management Corp (0.72%). Insiders that own company stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, James M Mock, Joel S Goldberg, Pascale Witz, Peter Barrett, Prahlad R Singh and Sylvie Gregoire.
View institutional ownership trends
.

How do I buy shares of PerkinElmer?

Shares of PKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $157.91.

How much money does PerkinElmer make?

PerkinElmer (NYSE:PKI) has a market capitalization of $19.93 billion and generates $5.07 billion in revenue each year. The medical research company earns $943.16 million in net income (profit) each year or $5.34 on an earnings per share basis.

How many employees does PerkinElmer have?

The company employs 16,700 workers across the globe.

Does PerkinElmer have any subsidiaries?

The following companies are subsidiares of PerkinElmer: 2Cure LLC, Analytica of Branford, Applied Biosystems, Arnel Inc., ArtusLabs, Beijing Huaan Magnech Bio-Tech Co. Ltd., Beijing Meizheng Bio-Tech Co. Ltd., Beijing Meizheng Testing Lab Co. Ltd., Beijing OUMENG Biotechnology Co. Ltd., Bio Evolution SAS, BioLegend, BioLegend CNS Inc., BioLegend China Beijing Ltd., BioLegend Europe B.V., BioLegend France SAS, BioLegend GmbH, BioLegend Inc., BioLegend Japan KK, BioLegend Shenzhen Ltd., BioLegend Taiwan Ltd., BioLegend UK Ltd., BioLegend Ventures LLC, Bioo Scientific Corporation, Biosense Technologies Pvt Ltd., Boulder Diagnostics Europe GmbH, Caliper Life Sciences, Caliper Life Sciences Inc., Cambridge Research & Instrumentation Inc., CambridgeSoft, Ceiba Solutions, Chengdu PerkinElmer Medical Laboratory Co. Ltd., Cisbio Asia Pacific Ltd, Cisbio Bioassays SAS, Cisbio China Ltd., Cisbio.com, DIA.Metra S.R.L., DNA Laboratories Sdn. Bhd., Dani Analitica S.r.l., Dexela, Dharmacon Inc., EUROIMMUN AG, EUROIMMUN Brasil Medicina Diagnostica Ltda., EUROIMMUN Diagnostics España S.L., EUROIMMUN France SAS, EUROIMMUN Hangzhou Medical Laboratory Diagnostics Co. Ltd., EUROIMMUN Italia Diagnostica Medica S.r.l., EUROIMMUN Japan Co. Ltd., EUROIMMUN Medical Diagnostics Canada Inc., EUROIMMUN Medical Diagnostics China Co. Ltd., EUROIMMUN Medical Laboratory Diagnostics South Africa Pty Ltd., EUROIMMUN Medizinische Labordiagnostika AG, EUROIMMUN Polska Sp. z o.o., EUROIMMUN Portugal Unipessoal Lda., EUROIMMUN Schweiz AG, EUROIMMUN South East Asia Pte Ltd., EUROIMMUN Tianjin Medical Diagnostic Technology Co. Ltd., EUROIMMUN Turkey Tibbi Laboratuar Teşhisleri A.Ş., EUROIMMUN UK Ltd., EUROIMMUN US Inc., EUROIMMUN US Real Estate LLC, Geospiza, Guangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Hangzhou EUROIMMUN Medical Diagnostic Products Co. Ltd., Horizon Diagnostics Limited, Horizon Discovery, Horizon Discovery Biosciences Limited, Horizon Discovery Group Ltd., Horizon Discovery Inc., Horizon Discovery KK, Horizon Discovery Limited, Horizon Genomics GmbH, IDS Brasil Diagnósticos Ltda., Immunetics Inc., Immunodiagnostic Systems, Immunodiagnostic Systems Deutschland GmbH, Immunodiagnostic Systems France SAS, Immunodiagnostic Systems Holdings Limited, Immunodiagnostic Systems Inc., Immunodiagnostic Systems Limited, Immunodiagnostic Systems SA, Inochem S.A. de C. V., Integromics S.L., Jiangsu Meizheng Bio-Tech Co. Ltd., LabMetrix Technologies, Labtronics, Nexcelom Bioscience, Nexcelom Bioscience Holdings LLC, Nexcelom Bioscience Instruments Shanghai Co. Ltd., Nexcelom Bioscience LLC, Nexcelom Bioscience Ltd., NovaScreen Biosciences Corporation, OZ Systems International SARL, OZ Systems USA LLC, Omni International Inc., Optimization Zorn Corporation, Opto Technology, Orchid Biomedical Systems Pvt Ltd., Oxford Diagnostic Laboratories UK Limited, Oxford Immunotec, Oxford Immunotec Asia Ltd, Oxford Immunotec Global Limited, Oxford Immunotec Ireland Limited, Oxford Immunotec KK, Oxford Immunotec Limited, Oxford Immunotec Shanghai Medical Device Co. Ltd., Oxford Immunotec USA Inc., Pediatrix Medical Group - Newborn Metabolic Screening Business, Perkin Elmer Chile Ltda., Perkin Elmer Instruments Philippines Corporation, Perkin Elmer Italia SpA, Perkin Elmer Sdn. Bhd., Perkin Elmer Yuhan Hoesa, Perkin-Elmer Argentina S.R.L., Perkin-Elmer de Mexico S.A., PerkinElmer Argentina Holdings LLC, PerkinElmer Automotive Research Inc., PerkinElmer BV, PerkinElmer CV Holdings LLC, PerkinElmer Cellular Technologies Germany GmbH, PerkinElmer Danmark A/S, PerkinElmer Diagnostics Global Holdings S.à r.l., PerkinElmer Diagnostics Holdings Inc., PerkinElmer España S.L., PerkinElmer Finance Luxembourg S.à r.l., PerkinElmer Finland Oy, PerkinElmer Genetics Inc., PerkinElmer Genomics Sweden AB, PerkinElmer Germany Diagnostics GmbH, PerkinElmer Global Diagnostics S.C.A., PerkinElmer Global Financing S.à r.l., PerkinElmer Global Holdings S.à r.l., PerkinElmer Health Sciences B.V., PerkinElmer Health Sciences Canada Inc., PerkinElmer Health Sciences FZ-LLC, PerkinElmer Health Sciences Inc., PerkinElmer Health Sciences Puerto Rico LLC, PerkinElmer Health Sciences Pvt Ltd., PerkinElmer Healthcare Diagnostics Shanghai Co. Ltd., PerkinElmer Holding Luxembourg S.à r.l., PerkinElmer Holdings Inc., PerkinElmer Holdings Singapore Pte Ltd., PerkinElmer Hong Kong Ltd., PerkinElmer IVD Pte Ltd., PerkinElmer Inc., PerkinElmer India Pvt Ltd., PerkinElmer Informatics Inc., PerkinElmer Instruments Suzhou Co. Ltd., PerkinElmer International C.V., PerkinElmer Investments Ky, PerkinElmer Ireland Ltd., PerkinElmer Israel Ltd., PerkinElmer Japan Co. Ltd., PerkinElmer LAS Germany GmbH, PerkinElmer LAS UK Ltd., PerkinElmer Life Sciences International Holdings, PerkinElmer Life Sciences Singapore Pte. Ltd., PerkinElmer Limited, PerkinElmer Ltd., PerkinElmer Management Chengdu Co. Ltd., PerkinElmer Management Shanghai Co. Ltd., PerkinElmer Nederland B.V. , PerkinElmer Norge AS, PerkinElmer Oy, PerkinElmer Polska Sp. z o.o., PerkinElmer Pty. Ltd., PerkinElmer SAS, PerkinElmer Sağlık ve Çevre Bilimleri Ltd., PerkinElmer Schweiz AG, PerkinElmer Shanghai Equity Investment Fund L.P., PerkinElmer Shanghai Equity Investment Fund Management Co. Ltd., PerkinElmer Shared Services Sp. z o.o., PerkinElmer Singapore Pte Ltd., PerkinElmer South Africa Pty Ltd., PerkinElmer Sverige AB, PerkinElmer Taiwan Corporation, PerkinElmer UK Holdings Ltd., PerkinElmer VertriebsgmbH, PerkinElmer chemagen Technologie GmbH, PerkinElmer do Brasil Ltda., Perten Instruments, Perten Instruments AB, Perten Instruments GmbH, Perten Instruments of Australia Pty Ltd., Qognit Inc., RHS Ltd, RayAl Ltd., SIRION Biotech, SIRION Biotech GmbH, SIRION Biotech International Inc., Sage Labs LLC, Shandong Meizheng Bio-Tech Co. Ltd., Shanghai Haoyuan Biotech Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Shanghai Spectrum Instruments Co. Ltd., Signature Genomic Laboratories, Singapore Biosciences Pte Ltd., Solus Scientific Solutions Ltd., SonoVol Inc., Suomen Bioanalytiikka Oy, Surendra Genetic Labs, Suzhou PerkinElmer Medical Laboratory Co. Ltd., Suzhou Sym-Bio LifeScience, Suzhou Sym-Bio Lifescience Co. Ltd., Synthetx Limited, Tulip Diagnostics, Tulip Diagnostics Pvt Ltd., Vanadis Diagnostics, Vanadis Diagnostics AB, ViaCell, ViaCord LLC, VisEn Medical, VisEn Medical Inc., Wallac Oy, Wellesley B.V., Xenogen Corporation, ZeLab SAS, and chemagen Biopolymer-Technologie AG.
Read More

When was PerkinElmer founded?

PerkinElmer was founded in 1937.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.perkinelmer.com. The medical research company can be reached via phone at (781) 663-6900, via email at ir@perkinelmer.com, or via fax at 781-663-5985.

This page (NYSE:PKI) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.